Compare TSE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSE | CMMB |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 9.1M |
| IPO Year | 2014 | 2023 |
| Metric | TSE | CMMB |
|---|---|---|
| Price | $0.23 | $1.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 749.8K | 74.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.40 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | ★ N/A | $45.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.87 |
| 52 Week High | $4.66 | $3.86 |
| Indicator | TSE | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 27.26 | 56.77 |
| Support Level | N/A | $1.48 |
| Resistance Level | $0.51 | $2.80 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 0.33 | 78.46 |
Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.